In 16 months, we have registered more cancer clinical trials in Armenia, than throughout all the years before that – Gevorg Tamamyan
Last year, on February 4th I was doing a presentation about the cancer clinical trials in Armenia. On my first slide I showed the number “3”. The meaning was, that up to that date on clinicaltrials.gov there were only 3 clinical trials in cancer in Armenia. On that day we agreed that we are going to change that situation!
In May 2022 we established the Immune Oncology Research Institute. Among the goals of the Institute is to develop cancer research in Armenia and in the region.
Today, I was checking again the clinicaltrials.gov and currently, the number is “7”. In 16 months, we have registered more cancer clinical trials in Armenia, than throughout all the years before that. Moreover, these are Investigator Sponsored Trials (ISTs).
Those trials are:
1. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry (NCT05430971) – 13 centers from 11 countries already joined the Registry and around 20 are currently onboarding. First results just recently were submitted to the Society of Hematologic Oncology Annual Meeting.
2. Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001) (NCT05891821) – phase 2 study, starting recruiting patients this month
Agenus
3. Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone (NCT05872893) – phase 3 study, starting recruiting patients this month
4. Rare Embryonal Tumors of the Central Nervous System: International Registry (NCT05711992) – 6 centers from 5 countries already joined the Registry
This is just the beginning, and I am sure soon we will have more to present.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023